
Article 1 
Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

((1)) Table 3.1 is amended as follows:

((a)) The entries corresponding to the entries set out in Annex I are replaced by the entries set out in that Annex;
((b)) The entries set out in Annex II are inserted in accordance with the order of the entries set out in Table 3.1.
((2)) Table 3.2 is amended as follows:

((a)) The entries corresponding to the entries set out in Annex III are replaced by the entries set out in that Annex;
((b)) The entries set out in Annex IV are inserted in accordance with the order of the entries set out in Table 3.2.
Article 2 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Article 1 shall apply from 1 December 2013.
The harmonised classifications set out in Part 3 of Annex VI to Regulation (EC) No 1272/2008, as amended by this Regulation, may be applied before 1 December 2013.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 10 July 2012.
For the Commission
The President
José Manuel BARROSO
ANNEX I


Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard Statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
"009-016-00-2 trisodium hexafluoroaluminate [1] 237-410-6 [1] 13775-53-6 [1] STOT RE 1Acute Tox. 4Aquatic Chronic 2 H372H332H411 GHS07GHS08GHS09Dgr H372H332H411   
trisodium hexafluoroaluminate (cryolite) [2] 239-148-8 [2] 15096-52-3 [2]
603-012-00-X 2-ethoxyethanol;ethylene glycol monoethyl ether 203-804-1 110-80-5 Flam. Liq. 3Repr. 1BAcute Tox. 3Acute Tox. 4 H226H360FDH331H302 GHS02GHS08GHS06Dgr H226H360FDH331H302   
603-025-00-0 tetrahydrofuran 203-726-8 109-99-9 Flam. Liq. 2Carc. 2Eye Irrit. 2STOT SE 3 H225H351H319H335 GHS02GHS07GHS08Dgr H225H351H319H335 EUH019 STOT SE 3;H335: C ≥ 25 %Eye Irrit.2;H319: C ≥ 25 % 
613-016-00-3 fuberidazole (ISO);2-(2-furyl)-1H-benzimidazole 223-404-0 3878-19-1 Carc. 2Acute Tox. 4STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H351H302H373 (heart)H317H400H410 GHS07GHS08GHS09Wng H351H302H373 (heart)H317H410  M = 1 
617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. EFlam. Liq. 2Muta. 2 H242H225H341 GHS02GHS08Dgr H242H225H341"   

ANNEX II


Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard Statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
‘015-199-00-X tris[2-chloro-1-chloromethyl)ethyl] phosphate 237-159-2 13674-87-8 Carc. 2 H351 GSH08Wng H351   
015-200-00-3 indium phosphide 244-959-5 22398-80-7 Carc. 1BRepr. 2STOT RE 1 H350H361fH372 (lungs) GHS08Dgr H350H361fH372 (lungs)  STOT RE 1;H372: C ≥0,1 %Carc 1B;H350: C ≥0,01 %STOT RE 2;H373: 0,01 % ≤ C < 0,1 % 
015-201-00-9 trixylyl phosphate 246-677-8 25155-23-1 Repr. 1B H360F GHS08Dgr H360F   
015-202-00-4 tris(nonylphenyl) phosphite 247-759-6 26523-78-4 Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H317H400H410 GHS07GHS09Wng H317H410   
015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 2 H361f (causing atrophy of the testes) GHS08Wng H361f (causing atrophy of the testes)   
602-109-00-4 Hexabromocyclododecane [1] 247-148-4 [1] 25637-99-4[1] Repr. 2Lact. H361H362 GHS08Wng H361H362   
1,2,5,6,9,10-hexabromocyclododecane [2] 221-695-9[2] 3194-55-6[2]
606-143-00-0 abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] _ [1] 71751-41-2 [1] Repr. 2Acute Tox. 2Acute Tox. 1STOT RE 1Aquatic Acute 1Aquatic Chronic 1 H361dH300H330H372 (nervous system)H400H410 GHS06GHS08GHS09Dgr H361dH300H330H372 (nervous system)H410  STOT RE 1;H372: C ≥ 5 %STOT RE 2;H373: 0,5 % ≤C<5 %M = 10 000 
avermectin B1a (purity ≥80 %); [2] 265-610-3 [2] 65195-55-3 [2]
606-144-00-6 acequinocyl (ISO);3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 Skin Sens. 1STOT SE 1STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H317H370 (lung)(inhalation)H373 (blood system)H400H410 GHS07GHS08GHS09Dgr H317H370 (lung)(inhalation)H373 (blood system)H410  M = 1 000 
607-698-00-1 4-tert-butylbenzoic acid 202-696-3 98-73-7 Repr. 1BSTOT RE 1Acute Tox. 4 H360FH372H302 GHS07GHS08Dgr H360FH372H302   
612-281-00-2 leucomalachite green;N,N,N',N'-tetramethyl-4,4'-benzylidenedianiline 204-961-9 129-73-7 Carc. 2Muta. 2 H351H341 GHS08Wng H351H341   
616-205-00-9 Metazachlor (ISO);2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide 266-583-0 67129-08-2 Skin Sens. 1BCarc. 2Aquatic Acute 1Aquatic Chronic 1 H317H351H400H410 GHS07GHS08GHS09Wng H317H351H410  M = 100M = 100’ 

ANNEX III


Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
"009-016-00-2 trisodium hexafluoroaluminate [1] 237-410-6 [1] 13775-53-6 [1] Xn; R20T; R48/23/25N; R51-53 T; NR: 20-48/23/25-51/53S: (1/2-)22-37-45-61  
trisodium hexafluoroaluminate (cryolite) [2] 239-148-8 [2] 15096-52-3 [2]
603-012-00-X 2-ethoxyethanol;ethylene glycol monoethyl ether 203-804-1 110-80-5 R10Repr. Cat. 2; R60-61Xn; R20/22 TR: 60-61-10-20/22S: 53-45  E
603-025-00-0 tetrahydrofuran 203-726-8 109-99-9 F; R11-19Carc. Cat. 3; R40Xi; R36/37 F; XnR: 11-19-40-36/37S: (2-)(13-)16-29-33-36-37(-46) Xi; R36/37: C ≥ 25 % 
613-016-00-3 fuberidazole (ISO);2-(2-furyl)-1H-benzimidazole 223-404-0 3878-19-1 Carc. Cat. 3; R40Xn; R48/22Xn; R22Xi; R43N; R50-53 Xn; NR: 40-48/22-22-43-50/53S: (2)-22-36/37-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 O; R7F; R11Muta. Cat. 3, R68 O; F; XnR: 7-11-68S: (2-)3/7-14-16-23-36/37/39"  

ANNEX IV


Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
‘015-199-00-X tris[2-chloro-1-chloromethyl)ethyl] phosphate 237-159-2 13674-87-8 Carc. Cat. 3; R40 XnR: 40S: (2-)36/37  
015-200-00-3 indium phosphide 244-959-5 22398-80-7 Carc. Cat. 2; R45Repr. Cat. 3; R62T; R48/23 TR: 45–48/23–62S: 45- 53 T; R48/23: C ≥0,1%Carc Cat 2; R45: C ≥0,01%Xn; R48/20: 0,01%≤ C < 0,1% E
015-201-00-9 trixylyl phosphate 246-677-8 25155-23-1 Repr. Cat. 2; R60 TR: 60S: 53-45  
015-202-00-4 tris(nonylphenyl) phosphite 247-759-6 26523-78-4 Xi; R43N; R50-53 Xi; NR: 43-50/53S: 24-37-60-61  
015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. Cat. 3; R62 XnR: 62S: (2)-22-36/37.  
602-109-00-4 Hexabromocyclododecane [1] 247-148-4 [1] 25637-99-4[1] Repr. Cat. 3; R63 R64 XnR: 63-64S: 36/37-53  
1,2,5,6,9,10-hexabromocyclododecane [2] 221-695-9[2] 3194-55-6[2]
606-143-00-0 abamectin (combination of avermectin B1a and avermectin B1b) (ISO) [1] _ [1] 71751-41-2 [1] Repr. Cat. 3; R63T+; R26/28T; R48/23/25N; R50-53 T+; NR: 63-26/28-48/23/25-50/53S: 28-36/37-45-60-61 T; R48/23: C ≥ 5%Xn; R48/20: 0,5% ≤ C <5%N; R50-53: C ≥ 0,0025%N; R51-53: 0,00025% ≤ C <0,0025%R52-53: 0,000025% ≤ C<0,00025% 
avermectin B1a (purity ≥80%); [2] 265-610-3 [2] 65195-55-3 [2]
606-144-00-6 acequinocyl (ISO);3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate — 57960-19-7 T; R39/23Xi; R43N; R50-53 T; NR: 39/23-43-50/53,S: (2-)24-37-38-60-61 N; R50-53: C ≥ 0,025%N; R51-53: 0,0025% ≤ C < 0,025%R52-53: 0,00025% ≤ C < 0,0025% 
607-698-00-1 4-tert-butylbenzoic acid 202-696-3 98-73-7 Repr. Cat. 2; R60T; R48/23/24/25Xn; R22 TR: 60-22-48/23/24/25S: 53-45  E
612-281-00-2 leucomalachite greenN,N,N',N'-tetramethyl-4,4'-benzylidenedianiline 204-961-9 129-73-7 Carc. Cat. 3; R40Muta. Cat. 3; R68 XnR: 40-68S: (2-)36/37  
616-205-00-9 Metazachlor (ISO);2-chloro-N-(2,6-dimethylphenyl)-N-(1H-pyrazol-1-ylmethyl)acetamide 266-583-0 67129-08-2 R43Carc. Cat. 3; R40N; R50-53 Xn; NR: 40-43-50/53S: (2-)36-37-60-61 N; R50-53: C ≥ 0,25%N; R51-53: 0,025% ≤ C < 0,25%R52-53: 0,0025% ≤ C < 0,025%’ 
